DE69004081T2 - Verwendung der Stearidonsäure zur Behandlung von Entzündungserkrankungen. - Google Patents

Verwendung der Stearidonsäure zur Behandlung von Entzündungserkrankungen.

Info

Publication number
DE69004081T2
DE69004081T2 DE90109883T DE69004081T DE69004081T2 DE 69004081 T2 DE69004081 T2 DE 69004081T2 DE 90109883 T DE90109883 T DE 90109883T DE 69004081 T DE69004081 T DE 69004081T DE 69004081 T2 DE69004081 T2 DE 69004081T2
Authority
DE
Germany
Prior art keywords
treatment
inflammatory diseases
stearidonic acid
stearidonic
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE90109883T
Other languages
English (en)
Other versions
DE69004081D1 (de
Inventor
Michel Guichardant
Michel Rigaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Nestle SA
Original Assignee
Societe des Produits Nestle SA
Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe des Produits Nestle SA, Nestle SA filed Critical Societe des Produits Nestle SA
Application granted granted Critical
Publication of DE69004081D1 publication Critical patent/DE69004081D1/de
Publication of DE69004081T2 publication Critical patent/DE69004081T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE90109883T 1990-05-23 1990-05-23 Verwendung der Stearidonsäure zur Behandlung von Entzündungserkrankungen. Expired - Lifetime DE69004081T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90109883A EP0457950B1 (de) 1990-05-23 1990-05-23 Verwendung der Stearidonsäure zur Behandlung von Entzündungserkrankungen

Publications (2)

Publication Number Publication Date
DE69004081D1 DE69004081D1 (de) 1993-11-25
DE69004081T2 true DE69004081T2 (de) 1994-02-10

Family

ID=8204025

Family Applications (1)

Application Number Title Priority Date Filing Date
DE90109883T Expired - Lifetime DE69004081T2 (de) 1990-05-23 1990-05-23 Verwendung der Stearidonsäure zur Behandlung von Entzündungserkrankungen.

Country Status (7)

Country Link
US (1) US5158975A (de)
EP (1) EP0457950B1 (de)
JP (1) JP3065710B2 (de)
DE (1) DE69004081T2 (de)
DK (1) DK0457950T3 (de)
ES (1) ES2059880T3 (de)
IE (1) IE65969B1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10121252A1 (de) * 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260465A (en) * 1991-12-16 1993-11-09 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
CA2119000A1 (en) * 1993-03-19 1994-09-20 David Frederick Horrobin Formulation for use in smokers
DE4432633C2 (de) * 1994-09-14 1997-07-31 Singer Peter Dr Med Priv Doz Pharmazeutisches Präparat zur lokalen Behandlung von Schuppenflechte, Neurodermitis und Ekzem
WO1997046220A1 (en) * 1996-06-03 1997-12-11 Croda International Plc Vegetable oil compositions
US6340485B1 (en) 1996-06-03 2002-01-22 Croda International Plc Compositions and uses thereof
NZ334852A (en) * 1996-10-11 2001-05-25 Scotia Holdings Plc Use and preparation containing eicosapentaenoic acid (EPA; 20:5n-3) for treating schizophrenia
US5855893A (en) * 1997-02-14 1999-01-05 Elizabeth Arden Co., Division Of Conopco, Inc. Trichodesma lanicum seed extract as an anti-irritant in compositions containing hydroxy acids or retinoids
DE19757414A1 (de) 1997-12-23 1999-07-01 Nutricia Nv Fettmischung
US7138431B1 (en) 1998-02-23 2006-11-21 Wake Forest University Dietary control of arachidonic acid metabolism
US6107334A (en) * 1998-02-23 2000-08-22 Wake Forest University Dietary control of arachidonic acid metabolism
US6579551B1 (en) 1998-05-21 2003-06-17 Beech-Nut Nutrition Corporation Baby-food compositions containing egg yolk and methods therefor
US7413759B2 (en) * 1998-05-21 2008-08-19 Beech-Nut Nutrition Corporation Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
US7141266B2 (en) * 1998-05-21 2006-11-28 Beech-Nut Nutrition Corporation Baby-food compositions enhancing visual acuity and methods therefor
US6149964A (en) * 1998-05-21 2000-11-21 Beech-Nut Nutrition Corporation Egg yolk-containing baby food compositions and methods therefor
US6340705B1 (en) * 1999-09-10 2002-01-22 Monsanto Technology, Llc Use of α-linolenic acid metabolites for treatment or prevention of cancer
CA2304906A1 (en) * 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
US6667064B2 (en) * 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
EP1392278A4 (de) * 2001-05-14 2005-05-04 Martek Biosciences Corp Herstellung und verwendung einer polaren lipidreichen fraktion mit stearidonsäure und gamma-linolensäure aus pflanzensamen und mikroben
MXPA04008711A (es) * 2002-03-08 2004-12-13 Monsanto Technology Llc Tratamiento y prevencion de trastornos inflamatorios.
AU2002951913A0 (en) * 2002-10-08 2002-10-24 Chevis Agriservices & Consulting Pty. Limited Method of treatment
EP1637134A4 (de) * 2003-06-20 2010-01-27 Mochida Pharm Co Ltd Zusammensetzung zur prävention/behandlung von varizen
PT1656449E (pt) * 2003-08-21 2009-07-27 Monsanto Technology Llc Dessaturases dos ácidos gordos a partir de prímulas
EP1734947B1 (de) 2004-04-16 2015-04-15 Monsanto Technology, LLC Expression von fettsäuredesaturasen in mais
US20050266051A1 (en) * 2004-05-27 2005-12-01 The Procter & Gamble Company Pet food compositions and methods
US8431165B2 (en) * 2004-12-13 2013-04-30 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer and other diseases
US8092839B2 (en) * 2004-12-13 2012-01-10 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer and other diseases
EP1714564A1 (de) * 2005-04-21 2006-10-25 N.V. Nutricia Verfahren zur Behandlung oder Vorbehandlung von Lungeninsuffiziens
JP5207341B2 (ja) * 2006-10-26 2013-06-12 独立行政法人産業技術総合研究所 炎症性サイトカイン産生抑制剤
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
GB0814105D0 (en) * 2008-08-01 2008-09-10 Springdale Sustainable Develop Composition for accelerated production of collagen
US8060617B2 (en) * 2008-12-19 2011-11-15 Cisco Technology, Inc. Reserving network resources during scheduling of meeting event
US8372465B2 (en) 2010-02-17 2013-02-12 Bunge Oils, Inc. Oil compositions of stearidonic acid
MA39718A (fr) * 2014-04-09 2017-02-15 Dignity Sciences Ltd Compositions et méthodes d'utilisation de celles-ci

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386072A (en) * 1981-06-26 1983-05-31 Horrobin David F Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor
EP0087865B1 (de) * 1982-03-01 1986-10-01 Efamol Limited Pharmazeutische Zusammensetzung
GB8710780D0 (en) * 1987-05-07 1987-06-10 Scras Opthalmological application of eicosapentaenoic acid
US5225441A (en) * 1987-06-18 1993-07-06 Block Drug Company, Inc. Treatment of periodontal disease
US4843095A (en) * 1987-08-07 1989-06-27 Century Laboratories, Inc. Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10121252A1 (de) * 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne

Also Published As

Publication number Publication date
IE65969B1 (en) 1995-11-29
DK0457950T3 (da) 1994-03-07
EP0457950A1 (de) 1991-11-27
DE69004081D1 (de) 1993-11-25
US5158975A (en) 1992-10-27
JPH04226915A (ja) 1992-08-17
IE911450A1 (en) 1991-12-04
JP3065710B2 (ja) 2000-07-17
EP0457950B1 (de) 1993-10-20
ES2059880T3 (es) 1994-11-16

Similar Documents

Publication Publication Date Title
DE69004081D1 (de) Verwendung der Stearidonsäure zur Behandlung von Entzündungserkrankungen.
DE69724016D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
DE3585981D1 (de) Behandlung gewebedegenerativer entzuendungskrankheiten.
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
DE69109583D1 (de) Verfahren zur Behandlung von entzündlichen Darmerkrankungen.
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
NO894296L (no) Fremgangsmaate for behandling av leddgikt og betennelsessykdommer.
DE69630479D1 (de) Arzneimittel zur Behandlung von entzündlichen Herzkrankheiten
DE69109560T2 (de) Fungizide Zusammensetzung zur Behandlung von Saatgut.
DE3882775T2 (de) Zusammensetzung zur Behandlung von parodontaler Krankheit.
DE69519577D1 (de) Prednisolonmetasulfobenzoatzusammensetzung zur behandlung von entzündungserkrankung des darmes
DE3888056D1 (de) Oxadiazolyl-azabicycloheptane zur Behandlung von seniler Demenz.
DE3782028D1 (de) Verwendung von ketonderivaten zur behandlung von bewusstseinsstoerungen.
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
NO913117D0 (no) Fremgangsmaate for behandling av benoedeleggende sykdommer.
DE3785555T2 (de) Verwendung von guaifenesin zur behandlung urologischer beschwerden.
DE59101581D1 (de) Verwendung von efeu zur topischen behandlung der psoriasis.
DE69025967T2 (de) Aryl- oder Heteroaryl-1-alkyl-pyrrol-2-carbonsäure-Derivate, zur Behandlung von durch Interleukin-1 hervorgerufenen Erkrankungen
DE3866653D1 (de) Zusammensetzung fuer die behandlung der epidermis.
DE69103294D1 (de) Verwendung der 3-Oxygermylpropionsäure zur Behandlung und Prävention von Diabetes verursacht durch Autoimmunkrankheiten.
DE3877199T3 (de) Verfahren zur Behandlung der Kopfhaut.
DE69133542D1 (de) Katheter zur Behandlung von Prostaterkrankungen
ATE57094T1 (de) Mittel zur behandlung von erkrankungen der zahnwurzelhaut.
ATE75617T1 (de) Behandlung gewebedegenerativer entzuendungskrankheiten.
DE68906028T2 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition